Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Clinical Value of EMR3 in Early Diagnosis, Dynamic Monitoring, and Prognostic Assessment of Sepsis: A Multicenter Prospective Observational Study in China

NCT07896018 is registered in ClinicalTrials.gov with Sir Run Run Shaw Hospital as lead sponsor.

NCT NCT07896018 Recruiting Observational 3,000 participants (estimated) Started 2026 1 site

Follow this trial by email Email me the PDF

Get the NCT07896018 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Summary

Recruiting, started November 2026. Observational study, 3,000 participants (estimated). Lead sponsor Sir Run Run Shaw Hospital; China. Primary measure: Diagnostic Accuracy of Neutrophil EMR3 Expression for Sepsis. 7 linked papers (newest 2023).

How it compares

415 similar trials: same condition (Shock, Septic) and phase

Enrollment

This trial
3,000
Middle half
50 to 355
Median
100
Trials with a value
411

Months from start to completion

This trial
10
Middle half
12 to 36.7
Median
22.6
Trials with a value
409

Sites

This trial
1
Middle half
1 to 1
Median
1
Trials with a value
372
Posted results or a linked paper 45% 187 of 415 similar trials; this trial: yes

Registry record

As filed in ClinicalTrials.gov.

Title
Clinical Value of EMR3 in Early Diagnosis, Dynamic Monitoring, and Prognostic Assessment of Sepsis: A Multicenter Prospective Observational Study in China
Lead sponsor
Sir Run Run Shaw Hospital
Phase
Observational
Overall status
Recruiting
Start date
November 30, 2026
Completion date
September 30, 2027
Enrollment
3,000 (estimated)
Sites
1

Conditions

MeSH condition names; the registry's own terms follow.

Who could take part, where it ran, who ran it

As filed in ClinicalTrials.gov.

Sex
All
Minimum age
18 Years
Healthy volunteers
Yes
Study type
Observational
Sites
1
Countries
China
Lead sponsor
Sir Run Run Shaw Hospital

Arms

As registered; 4 arms.

Registered arms
Arm Type Interventions
Sepsis/Septic Shock
Show registry wording

Patients aged 18 years or older diagnosed with sepsis or septic shock according to the Sepsis-3 criteria. Neutrophil EMR3 expression will be assessed at baseline, 72 ± 12 hours, and day 7 ± 1 day, with an optional measurement at day 14 ± 2 days, using residual blood samples from routine clinical care. Clinical outcomes will be followed for 28 days.

Infection Without Sepsis
Show registry wording

Adult patients with confirmed or suspected infection who do not meet the Sepsis-3 diagnostic criteria for sepsis. Neutrophil EMR3 expression will be measured at baseline using residual blood samples from routine clinical care. This group will serve as a comparator for evaluating the diagnostic accuracy of EMR3 in identifying sepsis.

Noninfectious Critical Illness
Show registry wording

Adult critically ill patients with noninfectious conditions, such as trauma, postoperative inflammation, acute pancreatitis, acute heart failure, or pulmonary embolism, without evidence of infection based on final clinical adjudication. Baseline neutrophil EMR3 expression will be measured to evaluate its diagnostic specificity in distinguishing sepsis from noninfectious critical illnesses.

Healthy or Elective Surgical Controls
Show registry wording

Healthy adults undergoing routine health examinations or patients undergoing elective surgery who meet the study eligibility criteria. Baseline neutrophil EMR3 expression will be measured using residual blood samples to establish reference expression levels and evaluate the stability of the flow cytometry assay. This group will not be included in the primary diagnostic comparison.

Primary endpoints

Registered primary outcome measures; 1 primary.

Registered primary endpoints
Measure Time frame
Diagnostic Accuracy of Neutrophil EMR3 Expression for Sepsis At baseline (T0), within 6 hours of enrollment or initial ICU admission.
Show registry wording

The diagnostic accuracy of baseline neutrophil EMR3 expression for identifying sepsis will be evaluated using the area under the receiver operating characteristic curve (ROC-AUC), with a 95% confidence interval. EMR3 expression will be measured by flow cytometry using residual EDTA-anticoagulated whole blood. The primary comparison will be between patients with sepsis or septic shock and patients with infection without sepsis or noninfectious critical illness. Healthy or elective surgical controls will be excluded from the primary diagnostic comparison.

Papers

PubMed papers this trial cites; 7 papers, results papers first, then newest first.

+2 more papers

Source: PubMed, NCBI/NLM (public domain).

Lead sponsor's other trials

Sir Run Run Shaw Hospital, most recent start first.

Similar trials

Same condition (Shock, Septic) and phase, most recent start first.